BETZ STEPHEN F. (Chief Scientific Officer) sold 7.2% of their position (10.61K shares) of CRINETICS PHARMACEUTICALS, INC. on the open market
Open‑market sale worth $396.6K — a moderate reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 2 sales
Filed: 3/18/2026ACC: 0001628280-26-019498
Officer· Chief Scientific Officer
Since Oct 2021
-10.61K
Net shares
Net seller
$396.6K
Total sold
2
Open market trades
0B · 2S
2
Total transactions
10.61K disposed
Non-Derivative Transactions2
Common Stock
Direct
Shares
−6.37K
Price / share
$37.11
Trade value
$236.43K
% of position
4.3%
3/16/2026
147.71K→141.34K
Common Stock
Direct
Shares
−4.24K
Price / share
$37.77
Trade value
$160.18K
% of position
3.0%
3/16/2026
141.34K→137.10K
Total
Net shares
−10.61K
Net value
-$396.61K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 3/16/2026 | S · Sale | −6.37K | $37.11 | $236.43K | 4.3% | 147.71K | 141.34K |
| Common Stock Direct | 3/16/2026 | S · Sale | −4.24K | $37.77 | $160.18K | 3.0% | 141.34K | 137.10K |
| Total | −10.61K | -$396.61K | ||||||
Derivative Transactions0
No derivative transactions reported